메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Charles Champeaux Depond (Department of Neurosurgery, Hôpital privé Clairval - Ramsay Santé, Marseille, France) Luc Bauchet2 (2Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France) Dahmane Elhairech (Department of Neurosurgery, Hôpital privé Clairval - Ramsay Santé, Marseille, France) Philippe Tuppin (Direction de la Stratégie, des Etudes et des Statistiques, Caisse Nationale de L’Assurance Maladie, Paris, France) Vincent Jecko (Department of Neurosurgery, Pellegrin Hospital, Bordeaux, France) Joconde Weller (Direction de l’Information Médicale, Prospectives et Data Sciences (DIMData), Hôpital Saint-Joseph, Paris, France) Philippe Metellus (Department of Neurosurgery, Hôpital privé Clairval - Ramsay Santé, Marseille, France)
저널정보
대한뇌종양학회 Brain Tumor Research and Treatment Brain Tumor Research and Treatment Vol.12 No.3
발행연도
2024.7
수록면
162 - 171 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background This study aimed to assess the overall survival (OS) of patients after high-grade glio- ma (HGG) resection and to search for associated prognostic factors. Methods A random sample of ad hoc cases was extracted from the French medico-adminis- trative national database, Système National des Données de Santé (SNDS). We solely considered the patients who received chemoradiotherapy with temozolomide (TMZ/RT) after HGG surgery. Statistical survival methods were implemented. Results A total of 1,438 patients who had HGG resection at 58 different institutions between 2008 and 2019 were identified. Of these, 34.8% were female, and the median age at HGG resection was 63.2 years (interquartile range [IQR], 55.6–69.4 years). Median OS was 1.69 years (95% confi- dence interval [CI], 1.63–1.76), i.e., 20.4 months. Median age at death was 65.5 years (IQR, 58.5–71.8). OS at 1, 2, and 5 years was 78.5% (95% CI, 76.4–80.7), 40.3% (95% CI, 37.9–43), and 11.8% (95% CI, 10.2–13.6), respectively. In the adjusted Cox regression, female gender (HR=0.71; 95% CI, 0.63– 0.79; p<0.001), age at HGG surgery (HR=1.02; 95% CI, 1.02–1.03; p<0.001), TMZ treatment over 6 months after HGG surgery (HR=0.36; 95% CI, 0.32–0.4; p<0.001), bevacizumab (HR=1.22; 95% CI, 1.09–1.37; p<0.001), and redo surgery (HR=0.79; 95% CI, 0.67–0.93; p=0.005) remained significantly associated with the outcome. Conclusion The SNDS is a reliable source for studying the outcome of HGG patients. OS is better in younger patient, female gender, and those who complete concomitant chemoradiotherapy. Redo surgery for HGG recurrence was also associated with prolonged survival.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0